Lapatinib for treatment of advanced or metastasized breast cancer
systematic review
Keywords:
Breast neoplasms, Review, Antineoplastic agents, Antineoplastic protocols, Receptor, erbB-2Abstract
CONTEXT AND OBJECTIVE: Around 16% to 20% of women with breast cancer have advanced, metastasized breast cancer. At this stage, the disease is treatable, but not curable. The objective here was to assess the effectiveness of lapatinib for treating patients with advanced or metastasized breast cancer. DESIGN AND SETTING: Systematic review of the literature, developed at Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp). METHOD: Systematic review with searches in virtual databases (PubMed, Lilacs [Literatura Latino-Americana e do Caribe em Ciências da Saúde], Cochrane Library, Scirus and Web of Science) and manual search. RESULTS: Only one clinical trial that met the selection criteria was found. This study showed that lapatinib in association with capecitabine reduced the risk of cancer progression by 51% (95% confidence interval, CI: 0.34-0.71; P < 0.001), compared with capecitabine alone, without any increase in severe adverse effects. CONCLUSION: The combination of lapatinib plus capecitabine was more effective than capecitabine alone for reducing the risk of cancer progression. Further randomized clinical trials need to be carried out with the aim of assessing the effectiveness of lapatinib as monotherapy or in association for first-line or second-line treatment of advanced breast cancer.
Downloads
References
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):S4-66.
Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus com- bination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;(2):CD003372.
New and Emerging Technology Briefing. National Horizon Scanning Centre. Lapatinib (GW572016) for advanced or metastatic breast cancer. The University of Birmingham; 2005. Available from: http://www.haps.bham.ac.uk/publichealth/horizon/outputs/documents/2005/Lapatinib.pdf. Accessed in 2009 (Oct 28).
National Institute for Clinical Excellence. Guidance on the use of trastuzumab for the treat- ment of advanced breast cancer. London: National Institute for Clinical Excellence; 2002. Available from: http://www.nice.org.uk/nicemedia/pdf/advancedbreastcancerno34PDF.pdf. Accessed in 2009 (Oct 28).
Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26(3): 151-68.
Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006;11(10):1047-57.
Johnston S, Stebbing J. Breast cancer: metastatic in clinical evidence, issue 8. London: BMJ Publishing Group; 2002.
Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;(2):cd002747.
Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 11):1-5.
National Horizon Scanning Centre. New and Emerging Technology Briefing. Lapatinib (GW572016) for advanced or metastatic breast cancer. Available from: http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/496451/?query=GW572016&rank=100. Accessed in 2009 (Oct 28).
National Institute for Clinical Excellence. Guidance on the use of capecitabine for the treat- ment of locally advanced or metastatic breast cancer. Technology Appraisal
Available from: http://guidance.nice.org.uk/TA62. Accessed in 2009 (Nov12).
National Institute for Clinical Excellence. Guidance on the use of vinorelbine for the treatment of advanced breast cancer. London: National Institute for Clinical Excellence; 2002. Available from: http://www.burypct.nhs.uk/cg/nicepdf/niceta54.pdf. Accessed in 2009 (Oct 28).
National Institute for Clinical Excellence. Taxanes for the treatment of breast cancer. NICE Technology Appraisal Guidance. Available from: http://www.nice.org.uk/cat.asp?c=1122. Accessed in 2009 (Nov 12).
National Institute for Health and Clinical Excellence. Gemcitabine for the treatment of me- tastatic breast cancer. London: National Institute for Health and Clinical Excellence 2007. Available from: http://www.nice.org.uk/nicemedia/pdf/TA116guidance.doc. Accessed in 2009 (Oct 28).
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235(4785):177-82.
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advan- ced breast cancer. N Engl J Med. 2006;355(26):2733-43.
Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epider- mal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003;14(9):1346-63.
Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estro- gen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65(1):18-25.
Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2000;37(Suppl 4):S3-8.
Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist. 2005;10(3): 191-7.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787-99.
Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/ EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61(19): 7196-203.
Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by he- regulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ ErbB2 kinase inhibitor GW572016. Oncogene. 2004;23(3):646-53.
Sáez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006;12(2):424-31.
Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063-70.
Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advan- ced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006;11(4): 318-24.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal anti- body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-26.
Drugs for breast cancer. Treat Guidel Med Lett. 2005;3(29):1-6.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons Ltd; 2006. Available from: http://www.cochrane.org/resources/handbook/Handbook4.2.6Sep2006.pdf. Accessed in 2009 (Oct 27).
Geyer CE, Forster JK, Cameron D, et al. Scientific Special Session: Lapatinib in Trastuzumab Resistant Breast Cancer. In 42nd Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006; Atlanta. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_de-tail_view&confID=40&abstractID=90002. Accessed in 2009 (Nov 16).
Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-43.
Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine Levels of Evi- dence (May 2001). Available from: http://www.cebm.net/index.aspx?o=1047. Accessed in 2009 (Nov 12).
Food and Drug Administration. FDA Approves Tykerb for Advanced Breast Cancer Patients. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108866.htm. Accessed in 2009 (Oct 28).
Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small mo- lecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Journal of Clinical Oncology. 2005;23(16 Suppl 1). [abstract 3046]. Available from: http://www.cancer.net/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=31998. Accessed in 2009 (Oct 28).
ClinicalTrials.gov. Paclitaxel with/without GW572016 (lapatinib) as first line therapy for wo- men with advanced or metastatic breast cancer. Available from: http://www.clinicaltrials. gov/ct/show/NCT00075270?order=1. Accessed in 2009 (Oct 28).
ClinicalTrials.gov. ErbB2 over-expressing metastatic breast cancer study using paclita- xel, trastuzumab, and lapatinib. Available from: http://www.clinicaltrials.gov/ct/show/NCT00272987. Accessed in 2009 (Oct 29).
ClinicalTrials.gov . Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. Available from: http://www.clinicaltrials.gov/ct/show/NCT00073528. Accessed in 2009 (Oct 29).
Paoletti P. SVP MDC oncology. Tikerb at ASCO 2006. Available from: http://www.gsk.com/investors/presentations/2006/06072006-roundtable-paole.pdf. Accessed in 2009 (Nov 12).
Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Journal of Cli- nical Oncology. 2004;22(14 Suppl.):196. [abstract 3006]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/3006. Accessed in 2009 (Oct 29).
Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Journal of Clinical Oncology. 2005;23(Suppl 16):S193. [abstract 3004]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/3004?maxtoshow=&HITS=20&hits=20&RESULTFORMAT=&fulltext=Determining+relevant+biomarkers+from+tissue+and+serum+that+may+predict+response+to+single+agent+lapatinib+in+trastuzumab+refractory+metastatic+breast+cancer+&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT. Accessed in 2009 (Oct 29).
Burstein H, Storniolo AM, Franco S, et al. A phase II, open-label, multicenter study of la- patinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol. 2004;15(Suppl 3):iii27 (abstract 1040). Available from: http://annonc.oxfordjournals.org/cgi/reprint/15/suppl_3/iii27. Accessed in 2009 (Oct 29).
Lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer. ClinicalTrials.gov [Web site]. Available from: http://www.clinical-trials.gov/ct/show/NCT00320385?order=1. Accessed in 2009 (Apr 16).
Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT) [abstract]. Journal of Clinical Oncology. 2007;25(Suppl 18):S1012. Available from: http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/1012. Accessed in 2009 (Oct 28).
Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Journal of Clinical Oncology. 2006;24(Suppl 18):S503. Available from: http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/503?maxtoshow=&HITS=20&hits=20&RESULTFORMAT=&fulltext=Phase+II+trial+of+lapatinib+for+brain+metastases+in+patients+with+HER2_breast+cancer&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT. Accessed in 2009 (Oct 28).
Trudeau M, Johnston S, Kaufman, et al. Lapatinib (Tykerb®) monotherapy in patients (PTS) with recurrent inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Annals of Oncology. 2006;17(Supplement. 9):ix69. Available from: http://annonc.oxfordjournals.org/cgi/reprint/17/suppl_9/ix69?ijkey=ef1d5135af012af5c4251bfec1ac99e8573ec9f9&keytype2=tf_ipsecsha. Accessed in 2009 (Oct 28).
Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract]. Breast Cancer Research and Treatment. 2006;100(Suppl 1):S5.
Piccart-Gebhart MJ, Perez EA, Baselga J. ALTTO (adjuvant lapatinib and/or trastuzumab tre- atment optimization) study (BIG 2– 06/N063D/EGF106708): A phase III study for HER-2- overexpressing early breast cancer [abstract]. The Breast. 2006;15(Suppl 1):S5.
Moy B, Maltzman JD, Goss PE. Phase II study of lapatinib after completion of adjuvant therapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer. The Breast. 2007;16(Suppl 1):S47.
Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer. 2007;7(6):489-92.
ClinicalTrials.gov. Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimi- zation) Study. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00553358?term=lapatinib&type=Intr&cond=breast+cancer&intr=%22Paclitaxel%22&rank=15. Accessed in 2009 (Oct 29).
